VG Life Sciences Inc. (VGLS) 0.0700 $VGLS
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
VG Life Sciences Inc. Progress Update Phase I Cancer Study
GlobeNewswire - Thu Sep 04, 7:27AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its physician-initiated IND phase I study to test safety and tolerability of its patented technology in patients with advanced stage solid tumors.
VG Life Sciences, Inc. - Product Pipeline Review - 2014
M2 - Thu Jul 24, 6:06AM CDT
Summary
VG Life Sciences, Inc. Announces Filing of Form 10 with the SEC.
GlobeNewswire - Mon Jun 23, 3:48PM CDT
VG Life Sciences, Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
VG Life Sciences, Inc.'s Reports on Clinical Outcomes in Phase I Cancer Study
GlobeNewswire - Fri Mar 14, 5:07AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
PR Newswire - Thu Aug 08, 6:50PM CDT
VG Energy, an agricultural biotech company and wholly owned subsidiary of publicly traded VG Life Sciences Inc. (VGLS), announces today a $200,000 competitive grant from the Texas A&M AgriLife Research BioEnergy Initiatives Program for testing oil secretion technology.
VG Life Sciences, Inc. Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; UniQuest Reports on LipidMax
PR Newswire - Thu Jul 25, 5:00AM CDT
SANTA BARBARA, Calif., July 25, 2013 /PRNewswire/--- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today several advancements as it relates to its scientific advancements
VG Life Sciences, Inc. Announces Management Changes
PR Newswire - Thu Jul 18, 7:30AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces alterations in its corporate management and management structure.
VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
PR Newswire - Thu May 23, 10:24AM CDT
VG Energy, an agricultural biotech company, announces today a strategic alliance with DAK Renewable Research to conduct field trials using LipidMax to increase the corn oil yield. VG Energy is a majority owned subsidiary of VG Life Sciences, Inc. (OTC Pink: VGLS).
VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
PR Newswire - Thu Apr 04, 7:03AM CDT
VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
PR Newswire - Fri Mar 22, 8:00AM CDT
VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today that it has signed a two-year commitment to provide funding toward the operational needs of the company from current investor MedBridge, LLC, a leading provider of development, turnaround, partnership advising and revenue cycle management services for the medical and healthcare industries. During this period, MedBridge will also provide full administrative support for VG Life Sciences, allowing the company to focus on clinical development of its therapeutic pipeline.
VG Life Sciences Subsidiary, VGEnergy, Hires Chief Science Advisor
Business Wire - Thu Feb 28, 7:30AM CST
VG Life Sciences (OTC Pink: VGLS) announces that Martin B. Dickman, Ph.D., has joined its subsidiary VGEnergy, as Chief Science Advisor. In concert with the company's Board of Directors, Dr. Dickman will enhance the scientific rigor of the company's alternative energy core technology platform and expand development of a pipeline of products that enhance the lipid and sugar production in emerging market sectors, such as algal biofuels, and significantly, in more mature and much larger markets, such as corn and sugar cane.
VG Life Sciences Reports Positive Results from First Stage of Ovarian Cancer Clinical Trial Using Sorafenib (Nexavar) Combined with Hydroxychloroquine
Business Wire - Thu Jan 31, 7:30AM CST
--Company Proceeds to Second Set of Patients
VG Life Sciences Expands Ovarian Cancer Trial; Approved to Study Treatment of Breast, Colon, Lung, Liver and Pancreas Cancer
Business Wire - Mon Jan 14, 3:06PM CST
VG Life Sciences (OTC Pink: VGLS), has received approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the Company's ongoing physician-initiated Phase 1 clinical trial. The IRB action allows the study to immediately broaden scope to the treatment of all solid tumors, which includes a wide and diverse range of cancer types including breast, colon, lung, liver and pancreas cancer. Effective immediately, principal investigator Dr. Tyler Curiel will begin screening patients with all solid tumors to study the safety of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexevar(TM) by Bayer AG). VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
VG Life Sciences Inc. Progress Update Phase I Cancer Study
GlobeNewswire - Thu Sep 04, 7:27AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its physician-initiated IND phase I study to test safety and tolerability of its patented technology in patients with advanced stage solid tumors.
VG Life Sciences, Inc. - Product Pipeline Review - 2014
M2 - Thu Jul 24, 6:06AM CDT
Summary
VG Life Sciences, Inc. Announces Filing of Form 10 with the SEC.
GlobeNewswire - Mon Jun 23, 3:48PM CDT
VG Life Sciences, Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
VG Life Sciences, Inc.'s Reports on Clinical Outcomes in Phase I Cancer Study
GlobeNewswire - Fri Mar 14, 5:07AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
PR Newswire - Thu Aug 08, 6:50PM CDT
VG Energy, an agricultural biotech company and wholly owned subsidiary of publicly traded VG Life Sciences Inc. (VGLS), announces today a $200,000 competitive grant from the Texas A&M AgriLife Research BioEnergy Initiatives Program for testing oil secretion technology.
VG Life Sciences, Inc. Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; UniQuest Reports on LipidMax
PR Newswire - Thu Jul 25, 5:00AM CDT
SANTA BARBARA, Calif., July 25, 2013 /PRNewswire/--- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today several advancements as it relates to its scientific advancements
VG Life Sciences, Inc. Announces Management Changes
PR Newswire - Thu Jul 18, 7:30AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces alterations in its corporate management and management structure.
VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
PR Newswire - Thu May 23, 10:24AM CDT
VG Energy, an agricultural biotech company, announces today a strategic alliance with DAK Renewable Research to conduct field trials using LipidMax to increase the corn oil yield. VG Energy is a majority owned subsidiary of VG Life Sciences, Inc. (OTC Pink: VGLS).
VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
PR Newswire - Thu Apr 04, 7:03AM CDT
VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
PR Newswire - Fri Mar 22, 8:00AM CDT
VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today that it has signed a two-year commitment to provide funding toward the operational needs of the company from current investor MedBridge, LLC, a leading provider of development, turnaround, partnership advising and revenue cycle management services for the medical and healthcare industries. During this period, MedBridge will also provide full administrative support for VG Life Sciences, allowing the company to focus on clinical development of its therapeutic pipeline.
VG Life Sciences Subsidiary, VGEnergy, Hires Chief Science Advisor
Business Wire - Thu Feb 28, 7:30AM CST
VG Life Sciences (OTC Pink: VGLS) announces that Martin B. Dickman, Ph.D., has joined its subsidiary VGEnergy, as Chief Science Advisor. In concert with the company's Board of Directors, Dr. Dickman will enhance the scientific rigor of the company's alternative energy core technology platform and expand development of a pipeline of products that enhance the lipid and sugar production in emerging market sectors, such as algal biofuels, and significantly, in more mature and much larger markets, such as corn and sugar cane.
VG Life Sciences Reports Positive Results from First Stage of Ovarian Cancer Clinical Trial Using Sorafenib (Nexavar) Combined with Hydroxychloroquine
Business Wire - Thu Jan 31, 7:30AM CST
--Company Proceeds to Second Set of Patients
VG Life Sciences Expands Ovarian Cancer Trial; Approved to Study Treatment of Breast, Colon, Lung, Liver and Pancreas Cancer
Business Wire - Mon Jan 14, 3:06PM CST
VG Life Sciences (OTC Pink: VGLS), has received approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the Company's ongoing physician-initiated Phase 1 clinical trial. The IRB action allows the study to immediately broaden scope to the treatment of all solid tumors, which includes a wide and diverse range of cancer types including breast, colon, lung, liver and pancreas cancer. Effective immediately, principal investigator Dr. Tyler Curiel will begin screening patients with all solid tumors to study the safety of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexevar(TM) by Bayer AG). VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
